Navigation Links
Researchers identify a new gene with a key role in obesity and diabetes
Date:1/10/2013

Scientists observed that blocking the expression of the gene TRIP-Br2 in mice protects them against obesity and insulin resistance. The study shows that the gene modulates fat storage by regulating energy expenditure and lipolysis, the process which transforms fat into lipids for the body's energy consumption. If the gene expression is blocked, the mice increase their lipolysis and their energy expenditure, thus reducing their obesity.

Obesity is the result of an alteration in the processes that regulate food absorption and energy production. This alteration tips the balance towards excessive storage of fat. According to the researchers, understanding the regulation of the factors that control the storage, mobilisation and use of excess energy in fat cells (the adipocytes) can lead to the development of therapies for obesity and its related illnesses, such as type 2 diabetes.

In the words of Cristina Mallol, a researcher at the Universitat Autnoma de Barcelona and co-author of the study: "The protection of mice with no expression of the gene TRIP-Br2, and its selective elevation in the visceral fat of humans point the way to a future gene therapy to counteract obesity, insulin resistance and excess lipids in the blood".


'/>"/>

Contact: Octavi Lpez Coronado
octavi.lopez@uab.cat
34-935-813-301
Universitat Autonoma de Barcelona
Source:Eurekalert

Page: 1

Related biology news :

1. GW researchers find variation in foot strike patterns in predominantly barefoot runners
2. Joslin researchers identify important factor in fat storage and energy metabolism
3. UCSB researchers perform pioneering research on Type 2 diabetes
4. Researchers develop tool to evaluate genome sequencing method
5. Jackson Laboratory researchers provide definitive proof for receptors role in synapse development
6. Researchers discover genetic basis for eczema, new avenue to therapies
7. Thomas Jefferson University researchers discover new pathways that drive metastatic prostate cancer
8. Carin Görings remains identified by researchers at Uppsala University
9. CNIO researchers develop new databases for understanding the human genome
10. 3 Johns Hopkins researchers named AAAS Fellows
11. Leibniz Prizes 2013: DFG honors 11 outstanding researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/21/2016)... VILNIUS, Lithuania , Nov. 21, 2016 /PRNewswire/ ... identification and object recognition technologies, today announced that ... for smart cards was submitted for the ... and successfully passed all the mandatory steps of ... III evaluation is a continuing test of fingerprint ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , ... December 08, 2016 , ... ... FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced ... FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
Breaking Biology Technology: